Compared with Moderna and the Pfizer-BioNTech partnership, which already have their COVID-19 vaccines authorized for emergency use, CureVac seems a little late to the mRNA...
As the chapter closes on the first year of the COVID-19 pandemic, drugmakers are hard at work bolstering the defenses mounted in 2020—and they’re looking at...
Riding a wave of interest in mRNA-based vaccines, Germany’s CureVac is looking to rapidly drive manufacturing of its own shot candidate. After announcing a plan...
With two leading mRNA-based COVID-19 vaccines racing toward approvals, nations are looking to secure enough doses to get the winning shot—or shots—into patients’ arms as...
As Pfizer and Moderna dominate headlines with positive interim readouts for their COVID-19 vaccine candidates, other mRNA players are taking note. Germany’s CureVac, hot on the heels of...
With mRNA-based coronavirus vaccines from Pfizer and Moderna showing promise in late-stage studies, another company working on a mid-stage mRNA candidate has inked a large supply deal with...
While Pfizer’s COVID-19 vaccine turned in strong early efficacy numbers and NIAID director Anthony Fauci said he expects similar figures from Moderna, the new class...
The entire scientific community is cheering on Pfizer and BioNTech’s early COVID-19 vaccine data. Beyond the obvious boon for fighting the pandemic, the 90% efficacy...
The entire scientific community is cheering on Pfizer and BioNTech’s early COVID-19 vaccine data. Beyond the obvious boon for fighting the pandemic, the 90% efficacy...
LONDON: A major non-profit health emergencies group has set up a global laboratory network to assess data from potential Covid-19 vaccines, allowing scientists and drugmakers...